GLS2 and acute myeloid leukemia: These results suggest that TAp73 promotes the serine biosynthesis pathway through transcriptional upregulation of the GLS-2 and the subsequent conversion of glutamine to glutamate in AML, and that the inhibition of TAp73 can potentially be exploitable for AML treatment.